Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026

Cellectar Biosciences, Inc.

Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.
Cash $13.2M at Dec 31, 2025, expected to fund operations into Q3 2026.
Plans to submit Conditional Marketing Authorization for iopofosine I 131 to EMA in Q3 2026.
Initiated Phase 1b study of CLR 125 in triple negative breast cancer; early data mid-2026.
Received FDA Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory WM.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cellectar Biosciences, Inc. reported the year ended December 31, 2025 results: net income $21.8 million, EPS $8.35 per basic and diluted share.

Period: the year ended December 31, 2025
Net income: $21.8 million
EPS: $8.35 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the full year ending December 31, 2025, was $21.8 million or $8.35 per basic and diluted share

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-023169

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.